Manchester, UK (October 27, 2011) Specialist electrochemical sensor manufacturer Analytical Technology Inc. today announces that it has been awarded a framework agreement to supply and install bufferless chlorine monitoring systems to Yorkshire Water. An in-depth technical evaluation was carried out by Yorkshire Water, in which Analytical Technology’s products were compared with a competitor’s against benchmark buffered units. Following this extensive process, Analytical Technology secured the agreement and commenced an asset replacement scheme for over 450 chlorine monitors.
The evaluation period lasted eight months and Analytical Technology’s bufferless chlorine monitors were tested using a wide variety of water types at four different water treatment works. During this time, the Analytical Technology monitors required very little maintenance and calibration, reflecting the company’s vast experience with membrane technology. This trial established that the monitor’s membranes would not need replacing for at least six months at all but a small minority of sites with high manganese levels.
Yorkshire Water continually monitors water from its 59 treatment plants with samples taken from 363 reservoirs where treated water is stored. In a typical year, more than 500,000 tests are carried out on water samples to ensure it meets exacting standards. The first phase of Analytical Technology’s framework agreement has been successfully completed with 75 chlorine monitors installed at 12 Yorkshire Water sites in the North and Dales areas. This includes a mixture of buffered, bufferless and pH corrected units, which are deployed depending on water quality and expected pH range. Additionally, funding for the second phase has recently been approved, in which a region wide asset replacement of chlorine monitors will be completed. This will include the installation of 377 chlorine monitors into an additional 31 water treatment plants and 20 secondary chlorination sites.
Rod Black, Asset Reliability Manager at Yorkshire Water said: “The instruments have performed well with little or no issues; chlorine control has been good and has not contributed to any call outs. It is nice to have standard instruments which can be calibrated and cleaned easily.” Alan Henson, Project Manager at Yorkshire Water commented: “Analytical Technology came out comfortably the best performer in our rigorous selection process, and the company’s vast experience with membrane technology places them ahead of most of their competitors who are only just adopting the technology. Once the roll-out has been completed, the scheme will have realised around £335K of OPEX savings per annum for Yorkshire Water and operators will no longer have to manhandle 25 litre containers of buffer around our sites. Analytical Technology has provided an excellent service and it is a pleasure working with a company who are very customer focussed.”
Dr. Michael Strahand, General Manager Europe at Analytical Technology added: “This agreement confirms that Analytical Technology’s chlorine monitors are unrivalled in the market, maintaining our position as one of the leading suppliers of water monitoring systems in the UK. Our top quality instrumentation is backed up by our commitment to delivering industry leading customer service and this new framework agreement is a great reward for our hard-working and dedicated team.”
Analytical Technology is a UK and European specialist electrochemical sensor manufacturer that supplies both water and gas monitoring instrumentation. The company was set up in 1998 and from then on has enjoyed increasing success. This new framework agreement to supply bufferless chlorine monitors to Yorkshire Water now means Analytical Technology provides instrumentation to 7 out of the 10 major utility companies in the UK. Analytical Technology’s wide range of water monitors includes peracetic acid, hydrogen peroxide, residual sulphite and several chlorine monitors. The company’s products aim to provide simpler installation, easier operation, regulatory compliance and lower cost, all combined with first class customer service.
For more information on Analytical Technology’s water and gas monitoring instrumentation, please call +44(0)1457 873 318, e-mail sales@atiuk.com or visit www.analyticaltechnology.com.
For further press information please contact: Lindsay Baldry, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: ati@scottpr.com
Thursday 27 October 2011
Monday 24 October 2011
Exco InTouch Wins Deloitte Technology Fast 50 Award in Recognition of Significant Growth
(Sawbridgeworth, UK, October 24 2011) Exco InTouch, the leading provider of patient communication solutions for the pharmaceutical and healthcare sectors, today announced that it is a winner of the 2011 Deloitte Technology Fast 50. The awards, now in their 14th year, are an independent ranking of the 50 fastest growing technology companies in the UK, based on percentage growth in revenue over five years. Exco InTouch was placed as the 44th fastest growing company in the country and the 7th fastest growing company in the South East region. Receipt of the Fast 50 award is a significant achievement, recognising growth based on innovation and entrepreneurship. Exco InTouch’s win comes on the back of a recent growth investment from leading growth equity and venture capital group Scottish Equity Partners (SEP).
Exco InTouch, whose clients include nine of the world’s top 10 pharmaceutical businesses, offers an innovative suite of patient-focused services which are delivered using a combination of cell-phone and internet technology. Used in clinical trials, the company’s services benefit both patients and pharmaceutical clients, providing patient recruitment and retention support. These unique services result in improved overall compliance and the facilitation of the electronic capture of patient reported outcomes data (ePRO) during clinical trials and in Late Phase observational studies. The business, which employs some 40 staff, has its headquarters in the UK and offices in the United States and recently opened a second UK office in Nottingham to accommodate up to 30 more staff.
With the recent £3m investment from SEP, Exco InTouch is entering its next growth phase, enabling it to invest further in people, technology and infrastructure and to further enhance its revolutionary mobile technology platform. SEP has taken a minority stake in the company. Exco InTouch will use the funds to take advantage of significant growth opportunities in the clinical trial sector, particularly in the emerging mobile patient communication market. Demand for its services is growing exponentially as pharmaceutical companies are increasingly adopting smart technology to optimise clinical trial execution.
“Making the Deloitte Technology Fast 50 is a testament to a company’s commitment to technology”, says Mark Doleman, Regional Partner, Deloitte UK Technology Fast 50 and Technology Fast 500 EMEA Programmes. “With its 730% growth rate over five years, Exco InTouch has proven that its leadership has the vision and determination to grow in competitive conditions.”
“The Deloitte UK Technology Fast 50 is internationally recognised as being one of the most important business awards in the sector and we are thrilled to receive this accreditation”, comments Tim Davis, CEO of Exco InTouch. “Despite economic uncertainty, the past five years have proved highly successful for us, with particular growth in our ePRO and patient engagement services. We look forward to this continued growth in the future as sponsors increasingly recognise the benefits of our mobile technology in the healthcare and drug development sectors.”
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
For further press information please contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: exco@scottpr.com
About Exco InTouch:
Exco InTouch is the leading provider of regulatory compliant interactive mobile patient communication solutions for Patient Recruitment, Retention, Compliance, ePRO/eDiary and Late Phase studies. Using a combination of software and services, Exco InTouch solutions provide simple, quick and non-intrusive channels of communication that enables sponsors, CROs, sites and patient recruitment agencies, find the right patients; keep them in their studies; motivate them to maintain full compliance and facilitate the collection of quality patient data, thus ensuring a better overall patient experience.
These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.
About Deloitte:
In this press release references to Deloitte are references to Deloitte LLP, which is among the country's leading professional services firms.
Deloitte LLP is the United Kingdom member firm of Deloitte Touche Tohmatsu (‘DTT’), a Swiss Verein, whose member firms are legally separate and independent entities. Please see www.deloitte.co.uk/about for a detailed description of the legal structure of DTT and its member firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.
Deloitte Technology, Media & Telecommunications (TMT) Group
The Deloitte TMT Group is composed of service professionals who have a wealth of experience serving technology, media and telecommunications companies throughout the UK in areas including cable, communications providers, computers and peripherals, entertainment, media and publishing, networking, semiconductors, software, wireless, and related industries. These specialists understand the challenges that these companies face throughout all stages of their business growth cycle and are committed to helping them succeed. Deloitte is a leader in providing strategic, financial and operational assistance to its technology, media and telecommunications clients.
For more information, please visit www.deloitte.co.uk/tmt
Exco InTouch, whose clients include nine of the world’s top 10 pharmaceutical businesses, offers an innovative suite of patient-focused services which are delivered using a combination of cell-phone and internet technology. Used in clinical trials, the company’s services benefit both patients and pharmaceutical clients, providing patient recruitment and retention support. These unique services result in improved overall compliance and the facilitation of the electronic capture of patient reported outcomes data (ePRO) during clinical trials and in Late Phase observational studies. The business, which employs some 40 staff, has its headquarters in the UK and offices in the United States and recently opened a second UK office in Nottingham to accommodate up to 30 more staff.
With the recent £3m investment from SEP, Exco InTouch is entering its next growth phase, enabling it to invest further in people, technology and infrastructure and to further enhance its revolutionary mobile technology platform. SEP has taken a minority stake in the company. Exco InTouch will use the funds to take advantage of significant growth opportunities in the clinical trial sector, particularly in the emerging mobile patient communication market. Demand for its services is growing exponentially as pharmaceutical companies are increasingly adopting smart technology to optimise clinical trial execution.
“Making the Deloitte Technology Fast 50 is a testament to a company’s commitment to technology”, says Mark Doleman, Regional Partner, Deloitte UK Technology Fast 50 and Technology Fast 500 EMEA Programmes. “With its 730% growth rate over five years, Exco InTouch has proven that its leadership has the vision and determination to grow in competitive conditions.”
“The Deloitte UK Technology Fast 50 is internationally recognised as being one of the most important business awards in the sector and we are thrilled to receive this accreditation”, comments Tim Davis, CEO of Exco InTouch. “Despite economic uncertainty, the past five years have proved highly successful for us, with particular growth in our ePRO and patient engagement services. We look forward to this continued growth in the future as sponsors increasingly recognise the benefits of our mobile technology in the healthcare and drug development sectors.”
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
For further press information please contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA Tel: +44 1477 539539 Fax: +44 1477 539540 e-mail: exco@scottpr.com
About Exco InTouch:
Exco InTouch is the leading provider of regulatory compliant interactive mobile patient communication solutions for Patient Recruitment, Retention, Compliance, ePRO/eDiary and Late Phase studies. Using a combination of software and services, Exco InTouch solutions provide simple, quick and non-intrusive channels of communication that enables sponsors, CROs, sites and patient recruitment agencies, find the right patients; keep them in their studies; motivate them to maintain full compliance and facilitate the collection of quality patient data, thus ensuring a better overall patient experience.
These solutions are currently being used by hundreds of thousands of patients in over 70 countries, delivered in the local language and are fully compliant with HIPAA regulations, FDA CFR 21 Part 11 and all electronic communication privacy directives.
About Deloitte:
In this press release references to Deloitte are references to Deloitte LLP, which is among the country's leading professional services firms.
Deloitte LLP is the United Kingdom member firm of Deloitte Touche Tohmatsu (‘DTT’), a Swiss Verein, whose member firms are legally separate and independent entities. Please see www.deloitte.co.uk/about for a detailed description of the legal structure of DTT and its member firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.
Deloitte Technology, Media & Telecommunications (TMT) Group
The Deloitte TMT Group is composed of service professionals who have a wealth of experience serving technology, media and telecommunications companies throughout the UK in areas including cable, communications providers, computers and peripherals, entertainment, media and publishing, networking, semiconductors, software, wireless, and related industries. These specialists understand the challenges that these companies face throughout all stages of their business growth cycle and are committed to helping them succeed. Deloitte is a leader in providing strategic, financial and operational assistance to its technology, media and telecommunications clients.
For more information, please visit www.deloitte.co.uk/tmt
Tameside Hospital and Synergy Health Extend Partnership With Sterile Services Contract
Swindon, UK (24 October 2011) – Synergy Health, the leading provider of specialist outsourced services to healthcare providers, today announced that Tameside Hospital NHS Foundation Trust has renewed its relationship with the company with the signing of a sterile services agreement. The lifetime contract, worth approximately £5m, is a continuation of the long standing relationship between the two organizations. Synergy Health delivers a range of specialist outsourced services to healthcare providers across Europe and China. These services are aimed at supporting customers to improve the quality and efficiency of their activities, while reducing risks to patients and clients. This continued collaboration will allow the Trust to benefit from enhanced productivity.
The Trust runs Tameside Hospital in Ashton-Under-Lyne, Synergy Health has been running the Trust’s sterile service processing facilities for over ten years.
Thursday 20 October 2011
Synergy Health Hires Specialist Business Development Manager in Line with Continued Growth Strategy
Swindon, UK (20th October 2011) – Synergy Health, the leading provider of specialist outsourced services to healthcare providers, today announced the appointment of Steve Poynter as Business Development Manager. The new role is part of Synergy Health’s growth strategy and is in response to increased demand for its services.
Poynter’s extensive health experience will be put to good use helping the NHS to maximize limited resources while improving quality and safety. Recent successful partnerships based on this model include University Hospital Leicester, Sheffield, Knowsley and The Royal London with Synergy Health providing the decontamination of surgical instruments, which demonstrate how investment in expertise and collaboration results in increased patient safety and cost savings.
Tuesday 18 October 2011
Optibrium Expands StarDrop Availability with Apple Mac Compatibility
Delivering Enhanced Functionality to Guide Decisions in All Stages of Drug Discovery
CAMBRIDGE, UK, October 18, 2011 – Optibrium, a provider of software solutions for drug discovery, today launches StarDrop 5.1, an upgraded version of its innovative support tool which helps drug discovery scientists to guide key decisions in drug discovery and quickly achieve successful project outcomes. As a result of this upgrade, StarDrop’s unique capabilities to guide the design and selection of high quality, novel compounds are now available on the Apple Mac, a reflection of the increasing popularity of Macs within the industry.
The revolutionary StarDrop 5.1 is a powerful yet user friendly software package which combines predictive capabilities with intuitive approaches to quickly and confidently target compounds with a good balance of properties, thereby reducing wasted effort and speeding progress to identify effective lead and candidate drugs. StarDrop’s unique approach to ‘multi-parameter optimisation’ explicitly accounts for the uncertainty in drug discovery data, whether due to experimental variability or predictive error, to provide scientists with a rigorous, objective analysis on which to make rational decisions.
As well as compatibility with the Apple Mac, StarDrop 5.1 brings a number of significant enhancements to existing features of StarDrop. For example, there is a new method for creating ‘chemical space’ visualizations based on the latest machine learning algorithm for ‘visual clustering’, that helps to easily explore the diversity of a project’s chemistry and identify ‘hot spots’ of high quality chemistry for further investigation.
There are also improvements to StarDrop’s plug-in modules: The Auto-Modeller™ sees the addition of the ‘Random Forests’ technique to its extensive repertoire for building predictive models tailored to a project’s chemistry and data. The addition of this new method has also led to improved QSAR models in the ADME QSAR module, which provides predictions of key ADME properties. StarDrop’s P450 metabolism module has been upgraded to provide improved prediction of regioselectivity and lability of metabolism by Cytochrome P450 enzymes, specifically around N-oxidation pathways. Finally, in response to user feedback on the new Nova™ module, further advances allow the generation of novel, relevant compounds ideas, prioritised against a project’s required property profile, starting from multiple initial structures and filtered according to user-specified rules to avoid unwanted substructures.
Dr. Matthew Segall, CEO of Optibrium, explains “These latest developments within StarDrop 5.1 demonstrate Optibrium’s commitment to deliver leading-edge technology while simultaneously responding to user feedback in order to ensure that it is accessible in the most user-friendly way. We work with drug discovery scientists, project leaders and R&D directors to provide tools that support confident decision-making to focus resources and improve efficiency.”
For more information about StarDrop 5.1 and Optibrium’s software solutions please visit www.optibrium.com, alternatively please call +44 (0) 1223 815 900 or email info@optibrium.com
About Optibrium Ltd
Optibrium (www.optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups. Our mission is to continue to develop new technologies that will optimise project strategy, reduce wasted molecules and experiments, shorten timelines and improve the quality of candidate compounds for our clients. Optibrium’s primary product, StarDrop, is focused on the drug discovery industry, helping guide scientists to make decisions in the design and selection of high quality drug candidates. Visit the online community at http://www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.
For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, UK Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: optibrium@scottpr.com
CAMBRIDGE, UK, October 18, 2011 – Optibrium, a provider of software solutions for drug discovery, today launches StarDrop 5.1, an upgraded version of its innovative support tool which helps drug discovery scientists to guide key decisions in drug discovery and quickly achieve successful project outcomes. As a result of this upgrade, StarDrop’s unique capabilities to guide the design and selection of high quality, novel compounds are now available on the Apple Mac, a reflection of the increasing popularity of Macs within the industry.
The revolutionary StarDrop 5.1 is a powerful yet user friendly software package which combines predictive capabilities with intuitive approaches to quickly and confidently target compounds with a good balance of properties, thereby reducing wasted effort and speeding progress to identify effective lead and candidate drugs. StarDrop’s unique approach to ‘multi-parameter optimisation’ explicitly accounts for the uncertainty in drug discovery data, whether due to experimental variability or predictive error, to provide scientists with a rigorous, objective analysis on which to make rational decisions.
As well as compatibility with the Apple Mac, StarDrop 5.1 brings a number of significant enhancements to existing features of StarDrop. For example, there is a new method for creating ‘chemical space’ visualizations based on the latest machine learning algorithm for ‘visual clustering’, that helps to easily explore the diversity of a project’s chemistry and identify ‘hot spots’ of high quality chemistry for further investigation.
There are also improvements to StarDrop’s plug-in modules: The Auto-Modeller™ sees the addition of the ‘Random Forests’ technique to its extensive repertoire for building predictive models tailored to a project’s chemistry and data. The addition of this new method has also led to improved QSAR models in the ADME QSAR module, which provides predictions of key ADME properties. StarDrop’s P450 metabolism module has been upgraded to provide improved prediction of regioselectivity and lability of metabolism by Cytochrome P450 enzymes, specifically around N-oxidation pathways. Finally, in response to user feedback on the new Nova™ module, further advances allow the generation of novel, relevant compounds ideas, prioritised against a project’s required property profile, starting from multiple initial structures and filtered according to user-specified rules to avoid unwanted substructures.
Dr. Matthew Segall, CEO of Optibrium, explains “These latest developments within StarDrop 5.1 demonstrate Optibrium’s commitment to deliver leading-edge technology while simultaneously responding to user feedback in order to ensure that it is accessible in the most user-friendly way. We work with drug discovery scientists, project leaders and R&D directors to provide tools that support confident decision-making to focus resources and improve efficiency.”
For more information about StarDrop 5.1 and Optibrium’s software solutions please visit www.optibrium.com, alternatively please call +44 (0) 1223 815 900 or email info@optibrium.com
About Optibrium Ltd
Optibrium (www.optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups. Our mission is to continue to develop new technologies that will optimise project strategy, reduce wasted molecules and experiments, shorten timelines and improve the quality of candidate compounds for our clients. Optibrium’s primary product, StarDrop, is focused on the drug discovery industry, helping guide scientists to make decisions in the design and selection of high quality drug candidates. Visit the online community at http://www.optibrium.com/community/ for further discussions on improving the productivity of drug discovery.
For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, UK Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: optibrium@scottpr.com
Monday 17 October 2011
The TSP Shanghai Office Team!
We love this picture of our TSP China team on a group day out to celebrate the end of first year trading and a successful start to Quarter One of Year Two.
From left to right: Olive Zhang, Zoe Wang, Daisy Shao, Joyce Wang, Rae Wang, Jacky Cheng, Coco Gu, Lily Liu, May Lan.
Thursday 13 October 2011
Novozymes to showcase state of the art cGMP-grade hyaluronic acid (HA) at CPhI 2011
HA designed specifically to fill a gap in the market for medical device and pharmaceutical manufacturers looking for Q7 cGMP regulatory compliant ingredients with superior performance benefits.
NOTTINGHAM, UK – October 13, 2011 – Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will showcase its soon to be launched state of the art Q7 cGMP-grade hyaluronic acid (HA) at CPhI Worldwide 2011. The new Bacillus-derived HA has been developed to improve how customers process and formulate HA for medical device and pharmaceutical applications, helping to speed up product development and creating improved therapeutics. The product confers a range of unique performance advantages for medical devices, drug delivery and formulation and will be showcased on booth #42H55 in hall 4.2 at the Messe Frankfurt, October 25-27, in Frankfurt, Germany.
“Novozymes is delighted to be returning to CPhI to showcase the company’s soon to be launched Q7 cGMP HA”, comments Hans Ole Klingenberg, global marketing director at Novozymes. “Delegates will be able to see the HA and our team of experts will be on hand to provide insight into how it can be incorporated into their manufacturing processes to reduce testing time, save on manufacturing costs and take products to market faster.”
Novozymes’ HA has been developed to expand opportunities for HA across multiple applications in the pharmaceutical and medical device industries. Produced at Novozymes’ new facility in Tianjin, China, which has been designed exclusively for HA, the company uses a patented water based process which is run in compliance with ICH Q7 cGMP guidelines. The resulting HA is free of animal derived components and organic solvents, resulting in a high degree of purity and reduced risk of contamination. It offers high batch-to-batch consistency with tight control of molecular weight for improved formulation control, as well as the capability to dissolve up to five times faster than other commercially available sources of HA. In addition, superior heat stability permits autoclaving without significant loss of product viscosity.
The new HA can be customized further using Novozymes’ proprietary crosslinking technology to achieve a specified viscosity, allowing the product to be adapted for a range of drug delivery and medical device applications. From ophthalmology and dermal filling to osteoarthritis treatments and cancer treatment, the unique technology will assist customers to create improved therapeutics with real benefits for both manufacturers and patients.
Novozymes’ HA will be commercially available in December.
To learn more about Novozymes’ HA, please visit booth #42H55 in hall 4.2 at CPhI Worldwide 2011. Alternatively, please visit www.biopharma.novozymes.com.
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
NOTTINGHAM, UK – October 13, 2011 – Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, will showcase its soon to be launched state of the art Q7 cGMP-grade hyaluronic acid (HA) at CPhI Worldwide 2011. The new Bacillus-derived HA has been developed to improve how customers process and formulate HA for medical device and pharmaceutical applications, helping to speed up product development and creating improved therapeutics. The product confers a range of unique performance advantages for medical devices, drug delivery and formulation and will be showcased on booth #42H55 in hall 4.2 at the Messe Frankfurt, October 25-27, in Frankfurt, Germany.
“Novozymes is delighted to be returning to CPhI to showcase the company’s soon to be launched Q7 cGMP HA”, comments Hans Ole Klingenberg, global marketing director at Novozymes. “Delegates will be able to see the HA and our team of experts will be on hand to provide insight into how it can be incorporated into their manufacturing processes to reduce testing time, save on manufacturing costs and take products to market faster.”
Novozymes’ HA has been developed to expand opportunities for HA across multiple applications in the pharmaceutical and medical device industries. Produced at Novozymes’ new facility in Tianjin, China, which has been designed exclusively for HA, the company uses a patented water based process which is run in compliance with ICH Q7 cGMP guidelines. The resulting HA is free of animal derived components and organic solvents, resulting in a high degree of purity and reduced risk of contamination. It offers high batch-to-batch consistency with tight control of molecular weight for improved formulation control, as well as the capability to dissolve up to five times faster than other commercially available sources of HA. In addition, superior heat stability permits autoclaving without significant loss of product viscosity.
The new HA can be customized further using Novozymes’ proprietary crosslinking technology to achieve a specified viscosity, allowing the product to be adapted for a range of drug delivery and medical device applications. From ophthalmology and dermal filling to osteoarthritis treatments and cancer treatment, the unique technology will assist customers to create improved therapeutics with real benefits for both manufacturers and patients.
Novozymes’ HA will be commercially available in December.
To learn more about Novozymes’ HA, please visit booth #42H55 in hall 4.2 at CPhI Worldwide 2011. Alternatively, please visit www.biopharma.novozymes.com.
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
Tuesday 11 October 2011
Synergy Health (UK) Appoints The Scott Partnership to Support Hospital Sterile Services
Cheshire, UK (Date, 2011) – Global B2B strategic communications agency The Scott Partnership has been appointed by Synergy Health (UK) Ltd. to support growth in its Hospital Sterile Services division.
Synergy is a leading provider of outsourced and managed decontamination services for reprocessing surgical instruments, processing more than 60 million surgical instruments per year for Acute NHS Trusts, NHS primary care providers and healthcare operators in the private sector. With 18 sterile service facilities, Synergy is the UK’s market leader in the provision of this service.
The client is being managed by The Scott Partnership’s Healthcare division whose brief is to engage stakeholders around Synergy’s innovative operating model which improves service and instrument processing quality, while significantly reducing operating costs.
Mike Langhorn, Synergy’s Commercial Director said: “We chose The Scott Partnership for their invaluable NHS experience and wide knowledge of the healthcare sector. This makes them a valued partner in positioning our hospital sterile services as a viable solution to enhance patient safety, improve quality and reduce costs – critical to today’s NHS.”
“This welcome addition to The Scott Partnership’s portfolio is a significant step in our continued expansion - further strengthening our customer base and presence in the healthcare sector,” adds Kath Darlington, CEO. “This account very much plays to our strengths and joins many existing clients who specialise in contract outsourcing and where high-level clinical engagement is critical.”
Based near Manchester, UK, The Scott Partnership is a specialist business-to-business PR agency for the healthcare, scientific, technology and pharmaceutical industries and which has grown to become one of the leading communications consultancies in Europe. Founded in 1996, the company’s accelerated growth plan has seen it establish offices in Boston and Shanghai in the past three years as well as its recent acquisition of Kapler Communications, a Bedfordshire-based life sciences consultancy.
For more information on The Scott Partnership, please call +44 (0)1477 539 539. Alternatively e-mail business@scottpr.com or visit www.scottpr.com.
Synergy is a leading provider of outsourced and managed decontamination services for reprocessing surgical instruments, processing more than 60 million surgical instruments per year for Acute NHS Trusts, NHS primary care providers and healthcare operators in the private sector. With 18 sterile service facilities, Synergy is the UK’s market leader in the provision of this service.
The client is being managed by The Scott Partnership’s Healthcare division whose brief is to engage stakeholders around Synergy’s innovative operating model which improves service and instrument processing quality, while significantly reducing operating costs.
Mike Langhorn, Synergy’s Commercial Director said: “We chose The Scott Partnership for their invaluable NHS experience and wide knowledge of the healthcare sector. This makes them a valued partner in positioning our hospital sterile services as a viable solution to enhance patient safety, improve quality and reduce costs – critical to today’s NHS.”
“This welcome addition to The Scott Partnership’s portfolio is a significant step in our continued expansion - further strengthening our customer base and presence in the healthcare sector,” adds Kath Darlington, CEO. “This account very much plays to our strengths and joins many existing clients who specialise in contract outsourcing and where high-level clinical engagement is critical.”
Based near Manchester, UK, The Scott Partnership is a specialist business-to-business PR agency for the healthcare, scientific, technology and pharmaceutical industries and which has grown to become one of the leading communications consultancies in Europe. Founded in 1996, the company’s accelerated growth plan has seen it establish offices in Boston and Shanghai in the past three years as well as its recent acquisition of Kapler Communications, a Bedfordshire-based life sciences consultancy.
For more information on The Scott Partnership, please call +44 (0)1477 539 539. Alternatively e-mail business@scottpr.com or visit www.scottpr.com.
The World's Biggest Coffee Morning!
Last week we took part in a charity event for a very worthy cause, Macmillan Cancer Support. The coffee morning is a national event which started as a small gathering, organised by a local fundraising committee in 1990. It is now is a hugely recognised event, taking place in offices, schools, universities and fundraising societies all over the country. It has grown massively since its inception and has turned into the world’s biggest coffee morning, 43,000 people signed up and took part last year!
Monday 10 October 2011
Thermo Fisher Scientific Introduces New Informatics Solution for Water and Environmental Testing Laboratories
PHILADELPHIA (October 10, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced a new informatics solution specifically developed for laboratory professionals working in water and environmental testing laboratories. The Thermo Scientific Water and Environmental LIMS is preconfigured to enable customers to comply with water and environmental regulatory guidelines and requirements, and it is built on the comprehensive functionality provided by the company’s flagship laboratory information management system, Thermo Scientific SampleManager LIMS. The company will showcase the Water and Environmental LIMS at Thermo Scientific booth # 4145 during WEFTEC 2011, being held October 17 - 19, in Los Angeles.
Friday 7 October 2011
A Day at the Races
Friday 9th September was the first decent day, weather wise, that we had seen in a while. Perfect timing as it was the day of The Scott Partnership’s trip to the Chester Races. Our southern partners Kapler, along with our sister company Scott Brothers Ltd. came along for the day which made it a big day out. After an excited morning at work, we piled onto the coach at lunchtime clutching our copies of the daily Racing Post in hope of winning some money. On the coach we were given our county concourse badges for admission which allowed us access to more of the course than most other ticket options. We were able to see the Paddocks Parade Ring and the Winners Enclosure, as well as having access to fine dining, various bars and an exclusive champagne bar. A pretty good deal I’d say!
Thursday 6 October 2011
Thermo Fisher Scientific Leading Mass Spectrometry Systems Selected by CVUA-MEL to Ensure Food Safety with Rapid and Reliable Contaminant Analysis
SAN JOSE, California (October 05, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that the Chemical and Veterinary Analytical Institute Münsterland-Emscher-Lippe (CVUA-MEL) has standardized on Thermo Scientific LC-MS and GC-MS systems for routine analyses of contaminants in food, feed and human samples. The CVUA-MEL requires extremely high resolution and highly sensitive instruments that can analyze small molecular weight contaminants in samples quickly and accurately and to the lowest limits of detection (LOD). Following a call to tender, which involved evaluation testing and result comparisons of a broad range of competitor products, the CVUA-MEL selected the Thermo Scientific Exactive benchtop MS coupled with the Transcend TLX system and DFS high resolution GC-MS systems. For information on how the systems help the CVUA-MEL ensure regulatory compliance, increase sample throughput and achieve greater sensitivity and improved accuracy, please see a detailed case study which is available to download: www.thermoscientific.com/fsnews
Tuesday 4 October 2011
Thermo Fisher Scientific Announces New Method for Precise and Reliable Analysis of Oil
ECUBLENS, Switzerland (October 3, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has developed a new precise and reliable method for elemental analysis of oil samples in the petrochemical industry. The innovative method uses the Thermo Scientific ARL PERFORM’X X-ray fluorescence (XRF) spectrometer to create a flexible and high-performance solution that is capable of reaching detection limits of below 0.5 parts per million (ppm). The new method, which covers a wide range of applications including the analysis of sulfur in oil and lead in gasoline, is detailed in an application note entitled “Analysis of Oils,” available to download free-of-charge via www.thermoscientific.com/performx.
Petrochemical regulations are becoming increasingly strict and are demanding lower levels of quantification for key elements such as sulfur, nickel, vanadium and lead in products. Compliance with various norms, including ASTM D2622, ASTM D4927 and ISO 20884, requires a method that can offer high sensitivity and stability to ensure content conforms to regulatory limits. The new Thermo Fisher method uses wavelength dispersive XRF (WDXRF), which is increasingly being used for analyses in the petroleum industry and has many advantages over traditional methods. This technique offers excellent repeatability and resolution, particularly for light elements such as sodium and calcium. In addition, it allows oils to be measured directly without dilution, which significantly reduces sample preparation time and increases speed and throughput of analyses.
Designed for demanding laboratories, the ARL PERFORM’X system offers dual sample loading and is able to process more than 60 samples per hour, offering rapid and precise analysis of up to 84 elements including sulfur, nickel, vanadium and lead. The instrument provides the highest standards of safety with an innovative sample recognition capability that ensures safe and straightforward loading of liquids. With its helium shutter, the ARL PERFORM’X completely protects the goniometer from chemical attacks and thermo instability by separating the primary chamber for the spectral chamber. The system also offers unmatched stability and repeatability of results, making it ideally suited to solving complex composition problems in demanding industrial applications.
The ARL PERFORM’X instrument features the latest version of the state-of-the-art Thermo Scientific OXSAS software, which is able to operate with Microsoft Windows® 7 to ensure simple and trouble-free analyses. Users also benefit from a synoptic panel that mimics real-time operation and internal functioning of the instrument on a separate display screen, enabling users to monitor the status of their analyses and improve productivity as a result of the software’s fast and accurate reporting capabilities.
For more information about the new Thermo Scientific ARL PERFORM’X and to obtain a copy of the new application note, please call +1 800-532-4752, email analyze@thermofisher.com or visit www.thermoscientific.com/performx.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
###
Petrochemical regulations are becoming increasingly strict and are demanding lower levels of quantification for key elements such as sulfur, nickel, vanadium and lead in products. Compliance with various norms, including ASTM D2622, ASTM D4927 and ISO 20884, requires a method that can offer high sensitivity and stability to ensure content conforms to regulatory limits. The new Thermo Fisher method uses wavelength dispersive XRF (WDXRF), which is increasingly being used for analyses in the petroleum industry and has many advantages over traditional methods. This technique offers excellent repeatability and resolution, particularly for light elements such as sodium and calcium. In addition, it allows oils to be measured directly without dilution, which significantly reduces sample preparation time and increases speed and throughput of analyses.
Designed for demanding laboratories, the ARL PERFORM’X system offers dual sample loading and is able to process more than 60 samples per hour, offering rapid and precise analysis of up to 84 elements including sulfur, nickel, vanadium and lead. The instrument provides the highest standards of safety with an innovative sample recognition capability that ensures safe and straightforward loading of liquids. With its helium shutter, the ARL PERFORM’X completely protects the goniometer from chemical attacks and thermo instability by separating the primary chamber for the spectral chamber. The system also offers unmatched stability and repeatability of results, making it ideally suited to solving complex composition problems in demanding industrial applications.
The ARL PERFORM’X instrument features the latest version of the state-of-the-art Thermo Scientific OXSAS software, which is able to operate with Microsoft Windows® 7 to ensure simple and trouble-free analyses. Users also benefit from a synoptic panel that mimics real-time operation and internal functioning of the instrument on a separate display screen, enabling users to monitor the status of their analyses and improve productivity as a result of the software’s fast and accurate reporting capabilities.
For more information about the new Thermo Scientific ARL PERFORM’X and to obtain a copy of the new application note, please call +1 800-532-4752, email analyze@thermofisher.com or visit www.thermoscientific.com/performx.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.
###
Monday 3 October 2011
CHESHIRE B2B AGENCY THE SCOTT PARTNERSHIP ANNOUNCES SECOND ACQUISITION IN TWO MONTHS IN CONTINUED GROWTH STRATEGY
03 October 2011: Cheshire based B2B agency The Scott Partnership Ltd (www.scottpr.com) announces the acquisition of Cambridge-based scientific marketing agency Phoenix Marcom Ltd (www.phoenixmarcom.co.uk). The acquisition sees Phoenix move into the holding company of The Scott Partnership Ltd to operate as a wholly owned stand-alone business. The addition of Phoenix Marcom marks the second acquisition since July 2011 for Scott Partnership Holdings Ltd, as it continues to expand its offering in scientific markets with three strong autonomous brands.
CEO Kath Darlington explains "Phoenix Marcom is a strong, established business, with a solid record of scientific, full-service marketing in Europe. The company provides its clients with a broad portfolio of marketing services, and has an impressive customer base. Our intention is that Phoenix will remain autonomous, servicing its predominantly European clients, retaining its focus in the Cambridge area, via the existing Phoenix team. The founder of Phoenix Marcom, Paul Carter, will join The Scott Partnership to support our expansion in Europe. All five companies in Scott Partnership Holdings will now offer PR and marketing services, specializing in healthcare and life sciences markets worldwide."
Subscribe to:
Posts (Atom)